# US 2018/0333466 A1 · Postprandial gastrokinetic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0333466 A1
- Document ID: US20180333466A1
- Status: Published application
- Kind: A1
- Application number: 16/048,779
- Filed: 2018-07-30
- Published: 2018-11-22
- Earliest claimed: 2013-03-25
- Assignees: Zeria Pharmaceutical Co., Ltd.; Saitama University
- Applicants: Zeria Pharmaceutical Co., Ltd.; Saitama University
- Inventors: Takafumi SAKAI; Ichiro Sakata; Kayuri Kuroda; Makoto Yoshimura
- Web page: https://patentgrep.com/patent/US20180333466A1

## CPC

- A61K 38/2214: {Motilins}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

## Claims

### Claim 1

A postprandial gastrokinetic agent, comprising:
(A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients.

### Claim 2

A method for enhancing postprandial gastric motility, comprising:
administering an ingredient (A) which is ghrelin or a ghrelin agonist and an ingredient (B) which is motilin or a motilin agonist to a subject in need thereof such that an effective blood level of each of the ingredients (A) and (B) is achieved after food intake,
wherein after food intake is within about 30 minutes immediately after intake of a meal, and
timing of the administering of each of the ingredients (A) and (B) is determined in consideration of a time to achieve the effective blood level, which is about 20 minutes to about 60 minutes after oral administration and about 10 minutes after intravenous administration.

### Claim 3 (depends on 2)

The method according to claim 2, which treats a disease selected from the group consisting of diabetic gastroparesis, postoperative gastroparesis, and functional dyspepsia.

### Claim 4 (depends on 2)

The method according to claim 2, which treats diabetic gastroparesis.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the administering comprises orally administering the ingredients (A) and (B) from about 30 minutes before to immediately before intake of a meal such that the effective blood level is achieved about 20 minutes to about 60 minutes after oral administration of the ingredients (A) and (B), respectively.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the administering comprises orally administering the ingredients (A) and (B) simultaneously.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the administering comprises intravenously administering the ingredients (A) and (B) immediately after food intake such that the effective blood level is achieved about 10 minutes after intravenous administration of the ingredients (A) and (B), respectively.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the administering comprises intravenously administering the ingredients (A) and (B) simultaneously.

### Claim 9 (depends on 2)

The method according to claim 2, which treats postoperative gastroparesis.

### Claim 10 (depends on 2)

The method according to claim 2, which treats functional dyspepsia.

### Claim 11

A method of treating a human patient having a disease selected from the group consisting of diabetic gastroparesis, postoperative gastroparesis, and functional dyspepsia, comprising:
administering ghrelin or a ghrelin agonist and motilin or a motilin agonist to the human patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein diabetic gastroparesis is treated.

### Claim 13 (depends on 11)

The method of claim 11, wherein postoperative gastroparesis is treated.

### Claim 14 (depends on 11)

The method of claim 11, wherein functional dyspepsia is treated.

### Claim 15 (depends on 11)

The method of claim 11, wherein the administering comprises simultaneously administering ghrelin or a ghrelin agonist and motilin or a motilin agonist.
